Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genome editing iPSC to purposing enhancement of induce CD8 killer T cell function for regenerative immunotherapy

18 Apr 2024

Abstract excerpt

In recent years, immunotherapy has become a standard cancer therapy, joining surgery, chemotherapy, and radiation therapy. This therapeutic approach involves the use of patient-derived antigen-specific T cells or genetically modified T cells engineered with chimeric antigen receptors (CAR) or T cell receptors (TCR) that specifically target cancer antigens. However, T cells require ex vivo stimulation for...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to CRISPR and Genetic Engineering
Share to Nanowire Synthesis and Applications

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 38637837
DOI: 10.1186/s41232-024-00328-3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genome editing iPSC to purposing enhancement of induce CD8 killer T cell function for regenerative immunotherapyPMID 38637837Read ↗

Induced Pluripotent Stem Cell-Based Cancer Immunotherapy: Strategies and PerspectivesSemantic proximity Read ↗

Combining the induced pluripotent stem cell (iPSC) technology with chimeric antigen receptor (CAR)-based immunotherapy: recent advances, challenges, and future prospectsSemantic proximity Read ↗

Advances in Allogeneic Cancer Cell Therapy and Future Perspectives on “Off-the-Shelf” T Cell Therapy Using iPSC Technology and Gene EditingSemantic proximity Read ↗

Cell Fate Reprogramming in the Era of Cancer ImmunotherapySemantic proximity Read ↗

Induced Pluripotent Stem Cell (iPSC)–Derived Lymphocytes for Adoptive Cell Immunotherapy: Recent Advances and ChallengesSemantic proximity Read ↗

Engineered and banked iPSCs for advanced NK- and T-cell immunotherapiesSemantic proximity Read ↗

A clinically applicable and scalable method to regenerate T-cells from iPSCs for off-the-shelf T-cell immunotherapySemantic proximity Read ↗

Derivation of mimetic γδ T cells endowed with cancer recognition receptors from reprogrammed γδ T cellSemantic proximity Read ↗

Multiplexed iPSC platform for advanced NK cell immunotherapiesSemantic proximity Read ↗

An Alternative Cell Therapy for Cancers: Induced Pluripotent Stem Cell (iPSC)-Derived Natural Killer CellsSemantic proximity Read ↗

From induced pluripotent stem cell (iPSC) to universal immune cells: literature review of advances in a new generation of tumor therapiesSemantic proximity Read ↗

iPSC-Derived Natural Killer Cells for Cancer ImmunotherapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.